secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0000950170-22-002731
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics elects Carlo Incerti, M.D. to Board of Directors
------------------------------------------------------------------

- Dr. Incerti elected as Class I director, term expiring at 2024 annual meeting.
- Received option to purchase 39,139 shares at $8.69 per share (March 2 closing price).
- Option vests in equal monthly installments over three years; full acceleration on change of control.
- Annual cash compensation of $35,000 plus standard director equity grants and expense reimbursement.
- Board determined Dr. Incerti is an independent director under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022002731/0000950170-22-002731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022002731/dyn-20220302.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-002731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer